Merck & Co., ( NYSE:MRK ) has achieved a significant milestone in the realm of medical innovation with the recent approval of its groundbreaking treatment for a rare and life-threatening form of high blood pressure. The approval of the drug, known as sotatercept and to be marketed as Winrevair in the US, by the Food and Drug Administration (FDA) marks a pivotal...
The biggest pharma giants are easy to recognize. Johnson and Johnson, Pfizer, Moderna, Merck & Co, Danaher Corp, Thermo Fisher Scientific. All medications and pharmaceutical drugs come out of these drug corporations. Lab equipment, medical research, vaccines, and other life science developments come out of these conglomerate pharma giants.
Support and Resistance...
Navigating the Oncology Frontier with Harpoon Therapeutics Acquisition
In a significant strategic move, pharmaceutical giant Merck & Co. ( NYSE:MRK ) has announced its plans to acquire cancer drugmaker Harpoon Therapeutics Inc. ( NASDAQ:HARP ) in a transformative deal valued at $680 million. The move aims to solidify Merck's leadership position in the highly...
Hi, according to my analysis of mrk stock. The stock looks negative. The stock broke the bottom at the 106 level. It also broke the ascending channel to the upside, as shown in the analysis. These are all indications that the stock is still under pressure from sellers. good luck for everbody
The pool-season is about to start, and Merck has already secured its place on the water slide, which should take it further downwards below the support at $110.66. However, there is still a 35% chance that the share might catch a bubbling fountain which could push it above the resistance at $119.65. In that case, we would expect Merck to develop a new top in the...
Merck and Company
Short Term
We look to Sell at 93.34 (stop at 96.33)
We look to sell rallies. Price action looks to be forming a top. Although the bulls are in control, the stalling positive momentum indicates a turnaround is possible. There is scope for mild buying at the open but gains should be limited.
Our profit targets will be 86.55 and 83.96...
After hitting 100SMA, it went down and seems that found its support which worked several times before. It may attract the buyers again
12 months Consensus Price Target: $94.21
if you find my charts useful, please leave me "like" or "comment".
Please don't trade according to the ideas, rely on your own knowledge.
Thx
